Home › Compare › TRGNF vs EQR

TRGNF vs EQR: Dividend Comparison 2026

TRGNF yields 200.00% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRGNF wins by $119.32M in total portfolio value
10 years
TRGNF
TRGNF
● Live price
200.00%
Share price
$1.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$119.36M
Annual income
$60,176,096.29
Full TRGNF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — TRGNF vs EQR

📍 TRGNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRGNFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRGNF + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
TRGNF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRGNF
Annual income on $10K today (after 15% tax)
$17,000.00/yr
After 10yr DRIP, annual income (after tax)
$51,149,681.85/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, TRGNF beats the other by $51,146,435.18/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRGNF + EQR for your $10,000?

TRGNF: 50%EQR: 50%
100% EQR50/50100% TRGNF
Portfolio after 10yr
$59.70M
Annual income
$30,089,957.94/yr
Blended yield
50.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

TRGNF
No analyst data
Altman Z
2.5
Piotroski
3/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRGNF buys
0
EQR buys
0
No recent congressional trades found for TRGNF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRGNFEQR
Forward yield200.00% ✓4.73%
Annual dividend / share$2.00$2.77 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$119.36M ✓$40.5K
Annual income after 10y$60,176,096.29 ✓$3,819.61
Total dividends collected$112.49M ✓$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: TRGNF vs EQR ($10,000, DRIP)

YearTRGNF PortfolioTRGNF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$30,700$20,000.00$11,248$547.57+$19.5K → TRGNF
2$90,232$57,383.18$12,701$666.53+$77.5K → TRGNF
3$254,173$157,624.56$14,405$814.59+$239.8K → TRGNF
4$686,927$414,961.74$16,413$999.84+$670.5K → TRGNF
5$1,783,118$1,048,106.39$18,795$1,232.92+$1.76M → TRGNF
6$4,450,613$2,542,677.12$21,639$1,527.95+$4.43M → TRGNF
7$10,693,420$5,931,263.38$25,057$1,903.80+$10.67M → TRGNF
8$24,760,608$13,318,648.86$29,197$2,385.87+$24.73M → TRGNF
9$55,315,649$28,821,798.66$34,250$3,008.70+$55.28M → TRGNF
10$119,363,841$60,176,096.29$40,467$3,819.61+$119.32M → TRGNF

TRGNF vs EQR: Complete Analysis 2026

TRGNF — Stock

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.

Full TRGNF Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this TRGNF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRGNF vs SCHDTRGNF vs JEPITRGNF vs OTRGNF vs KOTRGNF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.